Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE−/− mice by downregulating the HMGB1-RAGE axis

[1]  F. Antohe,et al.  Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein , 2011, Cell and Tissue Research.

[2]  K. Peter,et al.  High-Mobility Group Box Protein 1 Neutralization Reduces Development of Diet-Induced Atherosclerosis in Apolipoprotein E–Deficient Mice , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[3]  Hong Jiang,et al.  Statins attenuate high mobility group box-1 protein induced vascular endothelial activation : a key role for TLR4/NF-κB signaling pathway , 2010, Molecular and Cellular Biochemistry.

[4]  Yong-ming Yao,et al.  [The effect of simvastatin on the expression of high mobility group box-1 protein in atherosclerotic rats]. , 2010, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue.

[5]  J. Liao,et al.  Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[6]  L. Cui,et al.  Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-κB expression , 2010, Neuroscience Letters.

[7]  M. Cooper,et al.  The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation , 2008, Diabetologia.

[8]  R. Ramasamy,et al.  Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. , 2008, The Journal of clinical investigation.

[9]  T. Kooistra,et al.  Mouse models for atherosclerosis and pharmaceutical modifiers. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[10]  R. Muraro,et al.  Suppression of Rage as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Haichao Wang,et al.  Role of HMGB1 in cardiovascular diseases. , 2006, Current opinion in pharmacology.

[12]  U. Landmesser,et al.  Nonlipid-lowering effects of statins , 2005, Current treatment options in cardiovascular medicine.

[13]  N. Kalinina,et al.  Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[14]  R. Muraro,et al.  The Receptor RAGE as a Progression Factor Amplifying Arachidonate-Dependent Inflammatory and Proteolytic Response in Human Atherosclerotic Plaques: Role of Glycemic Control , 2003, Circulation.

[15]  Michael Bustin,et al.  Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. , 2003, Blood.

[16]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[17]  T. Kislinger,et al.  RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice , 2002, Circulation.

[18]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[19]  M. Rosenfeld,et al.  Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo : possible mechanisms for gender differences in atherosclerosis. , 1999, Circulation research.

[20]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[21]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[22]  Michel Vaubourdolle,et al.  A protocol for isolation and culture of human umbilical vein endothelial cells , 2007, Nature Protocols.

[23]  Jonathan D. Smith,et al.  Quantitative assay for mouse atherosclerosis in the aortic root. , 2006, Methods in molecular medicine.